drugset / Trial / NCT01251731

Single and Multiple Dose Asian Bridging Study

NCT01251731

Phase 1 Completed 36 enrolled Eisai Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the single-dose (SD) pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of 10, 40, and 80 mg E5501 followed by a selected dose for multiple dosing (MD) in healthy Japanese, Chinese, and Caucasian subjects.

Timeline

Start
2010-07
Primary completion
2011-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Avatrombopag Small molecule 10 mg Oral
Subject Avatrombopag Small molecule 40 mg Oral
Subject Avatrombopag Small molecule 80 mg Oral

Indications

No indication recorded.